Permeation of Insulin, Calcitonin and Exenatide across Caco-2 Monolayers: Measurement Using a Rapid, 3-Day System

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Gupta, Vivek ^a   Doshi, Nishit ^a   Mitragotri, Samir ^a  

^a University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE INSULIN; BUTYRIC ACID; EXENDIN 4; FLUORESCEIN ISOTHIOCYANATE; SALCATONIN; SULFORHODAMINE B;

ARTICLE; CELL DIFFERENTIATION; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ABSORPTION; DRUG PENETRATION; DRUG TRANSPORT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; MONOLAYER CULTURE; VALIDATION PROCESS;

ANALYSIS OF VARIANCE; CACO-2 CELLS; CALCITONIN; CELL MEMBRANE PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC IMPEDANCE; HUMANS; INSULIN; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PEPTIDES; RHODAMINES; VENOMS;

EID: 84874543337     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057136     Document Type: Article

References (49)

1. Frokjaer S, Otzen DE, (2005) Protein drug stability: a formulation challenge. Nat Rev Drug Discov 4: 298-306.
2. Mahato RI, Narang AS, Thoma L, Miller DD, (2003) Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20: 153-214.
3. Whitehead K, Shen Z, Mitragotri S, (2004) Oral delivery of macromolecules using intestinal patches: applications for insulin delivery. J Control Release 98: 37-45.
4. Fasano A, (1998) Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol 16: 152-157.
5. Hamman JH, Enslin GM, Kotze AF, (2005) Oral delivery of peptide drugs: barriers and developments. BioDrugs 19: 165-177.
6. Lee HJ, (2002) Protein drug oral delivery: the recent progress. Arch Pharm Res 25: 572-584.
7. Morishita M, Peppas NA, (2006) Is the oral route possible for peptide and protein drug delivery? Drug Discov Today 11: 905-910.
8. Le Ferrec E, Chesne C, Artusson P, Brayden D, Fabre G, et al. (2001) In vitro models of the intestinal barrier. The report and recommendations of ECVAM Workshop 46. European Centre for the Validation of Alternative methods. Altern Lab Anim 29: 649-668.
9. Artursson P, Palm K, Luthman K, (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46: 27-43.
10. Hidalgo IJ, Raub TJ, Borchardt RT, (1989) Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96: 736-749.
11. Hilgers AR, Conradi RA, Burton PS, (1990) Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 7: 902-910.
12. Hubatsch I, Ragnarsson EG, Artursson P, (2007) Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2: 2111-2119.
13. Chong S, Dando SA, Morrison RA, (1997) Evaluation of Biocoat intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity. Pharm Res 14: 1835-1837.
14. Collett A, Sims E, Walker D, He YL, Ayrton J, et al. (1996) Comparison of HT29-18-C1 and Caco-2 cell lines as models for studying intestinal paracellular drug absorption. Pharm Res 13: 216-221.
15. Lentz KA, Hayashi J, Lucisano LJ, Polli JE, (2000) Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. Int J Pharm 200: 41-51.
16. Asa D, LaRocca P, (2008) Comparison of the BD BioCoat™ Intestinal Epithelial Environment with the Conventional 21-Day Caco-2 System. Available: http://www.bdbiosciences.com/external_files/dl/doc/tech_bulletin/live/web_enabled/tb416.pdf. BD Biosciences Technical Bulletin 416: 1-3.
17. Yamashita S, Konishi K, Yamazaki Y, Taki Y, Sakane T, et al. (2002) New and better protocols for a short-term Caco-2 cell culture system. J Pharm Sci 91: 669-679.
18. Souleimani A, Asselin C, (1993) Regulation of c-myc expression by sodium butyrate in the colon carcinoma cell line Caco-2. FEBS Lett 326: 45-50.
19. Yang T, Arnold JJ, Ahsan F, (2005) Tetradecylmaltoside (TDM) enhances in vitro and in vivo intestinal absorption of enoxaparin, a low molecular weight heparin. J Drug Target 13: 29-38.
20. Mayfield JA, White RD, (2004) Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 70: 489-500.
21. Munoz-Torres M, Alonso G, Raya MP, (2004) Calcitonin therapy in osteoporosis. Treat Endocrinol 3: 117-132.
22. Davidson MB, Bate G, Kirkpatrick P, (2005) Exenatide. Nat Rev Drug Discov 4: 713-714.
23. Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G, (1998) Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 6: 317-324.
24. Hilgendorf C, Spahn-Langguth H, Regardh CG, Lipka E, Amidon GL, et al. (2000) Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci 89: 63-75.
25. Nollevaux G, Deville C, El Moualij B, Zorzi W, Deloyer P, et al. (2006) Development of a serum-free co-culture of human intestinal epithelium cell-lines (Caco-2/HT29-5M21). BMC Cell Biol 7: 20.
26. Ichikawa H, Peppas NA, (2003) Novel complexation hydrogels for oral peptide delivery: in vitro evaluation of their cytocompatibility and insulin-transport enhancing effects using Caco-2 cell monolayers. J Biomed Mater Res A 67: 609-617.
27. Ma EL, Ma H, Liu Z, Zheng GX, Duan MX, (2006) In vitro and in vivo evaluation of a novel oral insulin formulation. Acta Pharmacol Sin 27: 1382-1388.
28. Thompson C, Cheng WP, Gadad P, Skene K, Smith M, et al. (2011) Uptake and transport of novel amphiphilic polyelectrolyte-insulin nanocomplexes by Caco-2 cells--towards oral insulin. Pharm Res 28: 886-896.
29. Song KH, Chung SJ, Shim CK, (2005) Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release 106: 298-308.
30. Youn YS, Jung JY, Oh SH, Yoo SD, Lee KC, (2006) Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Control Release 114: 334-342.
31. Wood KM, Stone GM, Peppas NA, (2010) The effect of complexation hydrogels on insulin transport in intestinal epithelial cell models. Acta Biomater 6: 48-56.
32. Sajeesh S, Bouchemal K, Marsaud V, Vauthier C, Sharma CP, (2010) Cyclodextrin complexed insulin encapsulated hydrogel microparticles: An oral delivery system for insulin. J Control Release 147: 377-384.
33. Woitiski CB, Sarmento B, Carvalho RA, Neufeld RJ, Veiga F, (2011) Facilitated nanoscale delivery of insulin across intestinal membrane models. Int J Pharm 412: 123-131.
34. Cetin M, Youn YS, Capan Y, Lee KC, (2008) Preparation and characterization of salmon calcitonin-biotin conjugates. AAPS PharmSciTech 9: 1191-1197.
35. Shah RB, Khan MA, (2004) Regional permeability of salmon calcitonin in isolated rat gastrointestinal tracts: transport mechanism using Caco-2 cell monolayer. AAPS J 6: e31.
36. Sinko PJ, Lee YH, Makhey V, Leesman GD, Sutyak JP, et al. (1999) Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT). Pharm Res 16: 527-533.
37. Youn YS, Chae SY, Lee S, Kwon MJ, Shin HJ, et al. (2008) Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation. Eur J Pharm Biopharm 68: 667-675.
38. Burton PS, Conradi RA, Ho NF, Hilgers AR, Borchardt RT, (1996) How structural features influence the biomembrane permeability of peptides. J Pharm Sci 85: 1336-1340.
39. Conradi RA, Hilgers AR, Ho NF, Burton PS, (1991) The influence of peptide structure on transport across Caco-2 cells. Pharm Res 8: 1453-1460.
40. Anand BS, Patel J, Mitra AK, (2003) Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2. J Pharmacol Exp Ther 304: 781-791.
41. Salamat-Miller N, Johnston TP, (2005) Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int J Pharm 294: 201-216.
42. Ho NF, Burton PS, Conradi RA, Barsuhn CL, (1995) A biophysical model of passive and polarized active transport processes in Caco-2 cells: approaches to uncoupling apical and basolateral membrane events in the intact cell. J Pharm Sci 84: 21-27.
43. Yang HT, Wang GJ, (2003) Transport and uptake characteristics of a new derivative of berberine (CPU-86017) by human intestinal epithelial cell line: Caco-2. Acta Pharmacol Sin 24: 1185-1191.
44. Basson MD, Turowski G, Emenaker NJ, (1996) Regulation of human (Caco-2) intestinal epithelial cell differentiation by extracellular matrix proteins. Exp Cell Res 225: 301-305.
45. Gomez G, Zhang T, Rajaraman S, Thakore KN, Yanaihara N, et al. (1995) Intestinal peptide YY: ontogeny of gene expression in rat bowel and trophic actions on rat and mouse bowel. Am J Physiol 268: G71-81.
46. Hardin JA, Buret A, Meddings JB, Gall DG, (1993) Effect of epidermal growth factor on enterocyte brush-border surface area. Am J Physiol 264: G312-318.
47. Brewis IA, Howell S, Hooper NM, Kenny AJ, Turner AJ, (1993) Membrane peptidase expression by confluent cultures of Caco-2 cells. Biochem Soc Trans 21 (Pt3): 252S.
48. Whitehead K, Karr N, Mitragotri S, (2008) Safe and effective permeation enhancers for oral drug delivery. Pharm Res 25: 1782-1788.
49. Soikkeli A, Sempio C, Kaukonen AM, Urtti A, Hirvonen J, et al. (2010) Feasibility evaluation of 3 automated cellular drug screening assays on a robotic workstation. J Biomol Screen 15: 30-41.